Wall Street's major averages took home gains on Friday, with the S&P 500 reclaiming the 6,000 level for the first time since late February, as sentiment was boosted by a strong May jobs report.

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in ...

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars.

Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...

Bristol-Myers Squibb Company's undervaluation offers over 20% upside potential despite headwinds. Click here to find out why ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.